Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05565729 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of LY3471851 in Healthy Participants
A Phase 1 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT05565729 is a Phase 1 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 41 participants.
The verdict
NCT05565729, a Phase 1 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two different formulations (test \& reference) of LY3471851 in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be collected. Participants will remain in the study for about 12 weeks, after receiving the study drug that is LY3471851.
Interventions
- DRUG Placebo
- DRUG LY3471851
- DRUG Levocetirizine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05565729
The ClinicalTrials.gov registry entry for NCT05565729 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05565729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05565729 about?
NCT05565729 is a clinical study titled "A Phase I Study of LY3471851 in Healthy Participants". The purpose of this study is to compare two different formulations (test \& reference) of LY3471851 in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur ...
What is the current status of trial NCT05565729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2022-10-05. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT05565729?
The interventions under investigation include: Placebo (DRUG), LY3471851 (DRUG), Levocetirizine (DRUG).
Who is sponsoring clinical trial NCT05565729?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.